Publications 2004

  1. Apateerapong W, Ananworanich J. Participation in randomized trials in developing countries. J Pediatr. 2004 Jan;144(1):140; author reply 140.
  2. Sirivichayakul S, Tirawatnapong T, Ruxrungtham K, Oelrichs R, Lorenzen SL, Xin KQ, Okuda K, Phanuphak P. Construction and immunogenicity study of a 297-bp humanized HIV V3 DNA of an approximated last common ancestor in mice. Asian Pac J Allergy Immunol. 2004 Mar;22(1):49-60.
  3. Ananworanich J. Antiretroviral therapy-related hyperlactatemia. Pediatr Infect Dis J. 2004 Apr;23(4):375; author reply 375-6.
  4. Chansritrakul S, Eiam-Ong S, Kansanabuch T, Wathanavaha A, Ruxrungtham K. Continous ambulatory peritoneal dialysis improves both the number and memory function of CD4 T cells in uremic patients. J Med Assoc Thai. 2004 Apr;87(4):389-94.
  5. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM; 2NN Study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004 Apr 17;363(9417):1253-63.
  6. Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA, Dore GJ. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS. 2004 May 21;18(8):1169-77.
  7. Phanuphak P. Antiretroviral treatment in resource-poor settings: what can we learn from the existingprogrammes in Thailand?. AIDS. 2004 Jun;18 Suppl 3:S33-8.
  8. Wood R, Phanuphak P, Cahn P, Pokrovskiy V, Rozenbaum W, Pantaleo G, Sension M, Murphy R, Mancini M, Kelleher T, Giordano M. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):684-92.
  9. Ungsedhapand C, Srasuebkul P, Cardiello P, Ruxrungtham K, Ratanasuwan W, Kroon ED, Tongtalung M, Juengprasert N, Ubolyam S, Siangphoe U, Emery S, Lange JM, Cooper DA, Phanuphak P; on Behalf of the HIV-NAT 002 and HIV-NAT 003 Study Team. Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection. J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):693-701.
  10. Ananworanich J, Pancharoen C, Sirivichayakul S, Buranapraditkun S, Apateerapong, W, Ubolyam S, Ruxrungtham K. Undetectable plasma HIV-1 RNA with strong gag-pol specific interferon-g ELISPOT response in an HIV-1 clade A/E-infected child untreated with antiretroviral therapy. Asian Pac J Allergy Immunol. 2004 Jun-Sep;22(2-3):165-9.
  11. Arduino RC, Nannini EC, Rodriguez-Barradas M, Schrader S, Losso M, Ruxrungtham K, Allende MC, Emery S, Fosdick L, Neaton J, Tavel JA, Davey RT, Lane HC Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT) Vanguard Group; ESPRIT Executive Committee. CD4 cell response to 3 doses of subcutaneous inteleukin 2: meta-analysis of 3 Vanguard Studies. Clin Infect Dis. 2004 Jul 1;39(1):115-22. Epub 2004 Jun 14.
  12. Ananworanich J, Cheunyam T, Teeratakulpisarn S, Boyd MA, Ruxrungtham K, Lange J, Cooper D, Phanuphak P. Creation of a drug fund for post-clinical trial access to antiretrovirals. Lancet. 2004 Jul 3-9;364(9428):101-2.
  13. Ruxrungtham K, Brown T, Phanuphak P. HIV/AIDS in Asia. Lancet. 2004 Jul 3-9;364(9428):69-82.
  14. Ruxrungtham K, Boyd M, Bellibas SE, Zhang X, Dorr A, Kolis S, Kinchelow T, Buss N, Patel IH. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. J Clin Pharmacol. 2004 Jul;44(7):793-803.
  15. Pancharoen C, Ananworanich J, Thisyakorn U. Immunization for persons infected with human immunodeficiency virus. Curr HIV Res. 2004 Oct;2(4):293-9.
  16. van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, Wood R, Bloch M, Katlama C, Kastelein JJ, Schechter M, Murphy RL, Horban A, Hall DB, Lange JM, Reiss P. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004 Oct;1(1):e19. Epub 2004 Oct 19.
  17. Autar RS, Ananworanich J, Apateerapong W, Sankote J, Hill A, Hirschel B, Cooper D, Lange J, Phanuphak P, Ruxrungtham K, Burger D. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily.J Antimicrob Chemother. 2004 Oct;54(4):785-90. Epub 2004 Aug 25.
  18. Safreed-Harmon K, Cooper DA, Lange JM, Duncombe C, Phanuphak P. The HIV Netherlands Australia Thailand research collaboration: lessons from 7 years of clinical research. AIDS. 2004 Oct 1;18(15):1971-8.
  19. Ananworanich J, Siangphoe U, Mahanontharit A, Hill A, Hirschel B, Ruxrungtham K. Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg. Antivir Ther. 2004 Dec;9(6):1035-6.